封面
市場調查報告書
商品編碼
1602332

基於人工智慧的臨床試驗市場:按組成部分、特徵、階段、技術、應用和最終用戶 - 2025-2030 年全球預測

AI-based Clinical Trials Market by Component (Services, Software), Function (Adverse Event Detection, Data Collection & Analysis, Patient Recruitment & Screening), Phase, Technology, Application, End-user - Global Forecast 2025-2030

出版日期: | 出版商: 360iResearch | 英文 184 Pages | 商品交期: 最快1-2個工作天內

價格

本網頁內容可能與最新版本有所差異。詳細情況請與我們聯繫。

2023年基於人工智慧的臨床試驗市場規模為65.2億美元,預計2024年將達到77.3億美元,複合年成長率為18.79%,預計2030年將達到217.9億美元。

基於人工智慧的臨床試驗市場包括利用人工智慧技術簡化臨床試驗流程並提高效率、準確性和速度。這包括患者招募、資料管理、監控和預測分析中的應用。這種需求源自於傳統臨床試驗模型效率低、高成本且耗時的過程,這使得人工智慧對於尋求徹底改變藥物開發的製藥公司來說成為有吸引力的選擇。人工智慧在臨床試驗中的最終用途主要是由製藥公司、生物技術公司和委外研發機構(CRO) 來最佳化臨床試驗設計、縮短時間並提供對患者資料,從而改善患者的治療結果。主要成長動力包括對個人化醫療的需求不斷成長、人工智慧在醫療保健領域的日益採用以及對更高效的藥物開發流程的需求。人工智慧的整合為該領域的參與者提供了巨大的機會,因為它可以顯著縮短新藥和治療方法的上市時間。然而,資料隱私問題、監管障礙以及對高品質資料集集的需求等挑戰可能會阻礙市場成長。為了克服這些限制,企業應該投資建立強大的資料基礎設施,確保遵守監管標準,並培養與人工智慧新興企業和技術供應商的夥伴關係。創新領域包括利用機器學習演算法進行預測分析、利用自然語言處理進行資料提取,以及利用人工智慧模型進行臨床試驗中基於風險的監控。透過專注於提高患者安全、簡化監管合規流程並促進即時試驗協調的人工智慧技術,業務成長可以大大受益。總體而言,由於人工智慧技術的進步以及對更高效、更具成本效益的臨床試驗解決方案的需求不斷成長,市場有望實現顯著成長,但持續成長需要解決根本挑戰。

主要市場統計
基準年[2023] 65.2億美元
預測年份 [2024] 77.3億美元
預測年份 [2030] 217.9億美元
複合年成長率(%) 18.79%

市場動態:揭示快速發展的基於人工智慧的臨床試驗市場的關鍵市場洞察

基於人工智慧的臨床試驗市場正因供需的動態交互作用而轉變。透過了解這些不斷變化的市場動態,公司可以準備好做出明智的投資決策、完善策略決策並抓住新的商機。全面了解這些趨勢可以幫助企業降低政治、地理、技術、社會和經濟領域的風險,同時也能幫助企業了解消費行為及其對製造業的影響。

  • 市場促進因素
    • 需要人工智慧來幫助推動和改進臨床試驗
    • 越來越需要降低醫療成本和硬體成本
    • 許多製藥公司擴大採用基於人工智慧的藥物開發技術
  • 市場限制因素
    • 缺乏個人參與導致失業率上升
    • 缺陷診斷的可能性
  • 市場機會
    • 基於人工智慧的臨床試驗的技術進步和創新
    • 大型製藥企業增加與人工智慧供應商的合資和合作關係
  • 市場挑戰
    • 對引入 EHR互通性的擔憂

波特五力:駕馭人工智慧臨床試驗市場的策略工具

波特的五力架構是了解以人工智慧為基礎的臨床試驗市場競爭格局的關鍵工具。波特的五力框架為評估公司的競爭地位和探索策略機會提供了清晰的方法。該框架可幫助公司評估市場動態並確定新業務的盈利。這些見解使公司能夠利用自己的優勢,解決弱點並避免潛在的挑戰,從而確保更強大的市場地位。

PESTLE分析:了解基於人工智慧的臨床試驗市場的外部影響

外部宏觀環境因素在塑造基於人工智慧的臨床試驗市場的績效動態方面發揮關鍵作用。對政治、經濟、社會、技術、法律和環境因素的分析提供了應對這些影響所需的資訊。透過調查 PESTLE 因素,公司可以更了解潛在的風險和機會。這種分析可以幫助公司預測法規、消費者偏好和經濟趨勢的變化,並幫助他們做出積極主動的決策。

市場佔有率分析 了解以人工智慧為基礎的臨床試驗市場的競爭格局

基於人工智慧的臨床試驗市場的詳細市場佔有率分析可以對供應商績效進行全面評估。公司可以透過比較收益、客戶群和成長率等關鍵指標來揭示其競爭地位。該分析揭示了市場集中、分散和整合的趨勢,為供應商提供了製定策略決策所需的洞察力,以應對日益激烈的競爭。

FPNV 定位矩陣基於人工智慧的臨床試驗市場供應商的績效評估

FPNV 定位矩陣是評估以人工智慧為基礎的臨床試驗市場供應商的關鍵工具。此矩陣允許業務組織根據商務策略和產品滿意度評估供應商,從而做出與其目標相符的明智決策。這四個象限使您能夠清晰、準確地分類供應商,以確定最能滿足您的策略目標的合作夥伴和解決方案。

策略分析和建議繪製基於人工智慧的臨床試驗市場的成功之路

基於人工智慧的臨床試驗市場的策略分析對於旨在加強其在全球市場的影響力的公司至關重要。透過考慮關鍵資源、能力和績效指標,公司可以識別成長機會並努力改進。這種方法使您能夠克服競爭環境中的挑戰,利用新的商機並取得長期成功。

本報告對市場進行了全面分析,涵蓋關鍵重點領域:

1. 市場滲透率:詳細檢視當前市場環境、主要企業的廣泛資料、評估其在市場中的影響力和整體影響力。

2. 市場開拓:辨識新興市場的成長機會,評估現有領域的擴張潛力,並提供未來成長的策略藍圖。

3. 市場多元化:分析近期產品發布、開拓地區、關鍵產業進展、塑造市場的策略投資。

4. 競爭評估與情報:徹底分析競爭格局,檢驗市場佔有率、業務策略、產品系列、認證、監理核准、專利趨勢、主要企業的技術進步等。

5. 產品開發與創新:重點在於有望推動未來市場成長的最尖端科技、研發活動和產品創新。

我們也回答重要問題,以幫助相關人員做出明智的決策:

1.目前的市場規模和未來的成長預測是多少?

2. 哪些產品、區隔市場和地區提供最佳投資機會?

3.塑造市場的主要技術趨勢和監管影響是什麼?

4.主要廠商的市場佔有率和競爭地位如何?

5. 推動供應商市場進入和退出策略的收益來源和策略機會是什麼?

目錄

第1章 前言

第2章調查方法

第3章執行摘要

第4章市場概況

第5章市場洞察

  • 市場動態
    • 促進因素
      • 需要人工智慧來幫助加速和改進臨床試驗
      • 越來越需要降低醫療成本和硬體成本
      • 大多數製藥公司已採用基於人工智慧的藥物開發技術
    • 抑制因素
      • 缺乏個人參與導致失業率上升
      • 可能診斷錯誤
    • 機會
      • 基於人工智慧的臨床試驗的技術進步和創新
      • 大型製藥公司正在擴大與人工智慧供應商的合資企業和合作夥伴關係
    • 任務
      • 對引入 EHR互通性的擔憂
  • 市場區隔分析
  • 波特五力分析
  • PESTEL分析
    • 政治的
    • 經濟
    • 社群
    • 技術的
    • 合法地
    • 環境

第6章基於人工智慧的臨床試驗市場:按組成部分

  • 服務
  • 軟體

第7章 人工智慧的臨床試驗市場:依功能分類

  • 不利事件檢測
  • 資料收集與分析
  • 病人招募和篩檢
  • 預測模型
  • 測試設計與最佳化

第8章基於人工智慧的臨床試驗市場分階段

  • 第一階段
  • 第二階段
  • 第三階段

第9章基於人工智慧的臨床試驗市場:按技術分類

  • 機器學習
  • 自然語言處理

第10章基於人工智慧的臨床試驗市場:按應用分類

  • 心血管疾病
  • 感染疾病
  • 代謝性疾病
  • 神經系統疾病
  • 腫瘤學

第11章 以人工智慧為基礎的臨床試驗市場:依最終使用者分類

  • 學術研究所
  • 合約調查機構
  • 醫院
  • 製藥和生物製藥公司

第12章美洲人工智慧臨床試驗市場

  • 阿根廷
  • 巴西
  • 加拿大
  • 墨西哥
  • 美國

第13章亞太地區基於人工智慧的臨床試驗市場

  • 澳洲
  • 中國
  • 印度
  • 印尼
  • 日本
  • 馬來西亞
  • 菲律賓
  • 新加坡
  • 韓國
  • 台灣
  • 泰國
  • 越南

第14章 歐洲、中東和非洲人工智慧臨床試驗市場

  • 丹麥
  • 埃及
  • 芬蘭
  • 法國
  • 德國
  • 以色列
  • 義大利
  • 荷蘭
  • 奈及利亞
  • 挪威
  • 波蘭
  • 卡達
  • 俄羅斯
  • 沙烏地阿拉伯
  • 南非
  • 西班牙
  • 瑞典
  • 瑞士
  • 土耳其
  • 阿拉伯聯合大公國
  • 英國

第15章競爭格局

  • 2023 年市場佔有率分析
  • FPNV 定位矩陣,2023
  • 競爭情境分析
  • 戰略分析和建議

公司名單

  • AiCure, LLC
  • Aiforia Technologies Oyj
  • Antidote Technologies, Inc.
  • Ardigen SA
  • Avantor, Inc.
  • BioAge Labs
  • BioSymetrics Inc.
  • Deep 6 AI Inc.
  • Envisagenics
  • Euretos Services BV
  • Exscientia PLC
  • GNS Healthcare
  • Google LLC by Alphabet Inc.
  • Innoplexus AG
  • InSilico Medicine
  • Intel Corporation
  • International Business Machines Corporation
  • Koninklijke Philips NV
  • Median Technologies
  • Nuritas Limited
  • Pharmaceutical Pipeline Enhancement Strategies, LLC
  • Saama Technologies, Inc.
  • Symplr Software LLC
  • Trials.ai, Inc. by ZS Associates, Inc.
  • Unlearn.AI, Inc.
Product Code: MRR-03559044807A

The AI-based Clinical Trials Market was valued at USD 6.52 billion in 2023, expected to reach USD 7.73 billion in 2024, and is projected to grow at a CAGR of 18.79%, to USD 21.79 billion by 2030.

The AI-based Clinical Trials market encompasses the utilization of artificial intelligence technologies to streamline the clinical trial process, enhancing efficiency, accuracy, and speed. This includes applications in patient recruitment, data management, monitoring, and predictive analytics. The necessity arises from the traditional clinical trial model's inefficiencies, high costs, and time-consuming processes, making AI an attractive alternative for pharmaceutical companies aiming to innovate drug development. AI applications in clinical trials are primarily end-used by pharmaceutical companies, biotechnology firms, and contract research organizations (CROs) to optimize trial designs, reduce timelines, and improve patient outcomes by providing deeper insights into patient data. Key growth drivers include increasing demand for personalized medicine, the growing adoption of AI in healthcare, and the need for more efficient drug development processes. The integration of AI can significantly reduce the time to market for new drugs and therapies, presenting a major opportunity for players in this space. However, challenges such as data privacy concerns, regulatory hurdles, and the need for high-quality data sets can impede market growth. To overcome these limitations, companies should invest in building robust data infrastructures, ensuring compliance with regulatory standards, and fostering partnerships with AI startups and technology providers. Areas of innovation include leveraging machine learning algorithms for predictive analytics, natural language processing for data extraction, and AI models for risk-based monitoring in trials. For business growth, focusing on AI technologies that enhance patient safety, streamline regulatory compliance processes, and facilitate real-time trial adjustments can yield substantial benefits. Overall, the market is poised for significant growth, driven by advancements in AI technologies and increasing demand for more efficient and cost-effective clinical trial solutions, although addressing underlying challenges is crucial for sustained progress.

KEY MARKET STATISTICS
Base Year [2023] USD 6.52 billion
Estimated Year [2024] USD 7.73 billion
Forecast Year [2030] USD 21.79 billion
CAGR (%) 18.79%

Market Dynamics: Unveiling Key Market Insights in the Rapidly Evolving AI-based Clinical Trials Market

The AI-based Clinical Trials Market is undergoing transformative changes driven by a dynamic interplay of supply and demand factors. Understanding these evolving market dynamics prepares business organizations to make informed investment decisions, refine strategic decisions, and seize new opportunities. By gaining a comprehensive view of these trends, business organizations can mitigate various risks across political, geographic, technical, social, and economic domains while also gaining a clearer understanding of consumer behavior and its impact on manufacturing costs and purchasing trends.

  • Market Drivers
    • Need for artificial Intelligence which helps in boosting and improving clinical trials
    • Rising needs to reduce healthcare costs and declining hardware costs
    • Increased adoption of AI-based drug development technology by most of the pharmaceutical companies
  • Market Restraints
    • Lack of personal involvement leading to a rise in unemployment rates
    • Possibility of a defective diagnosis
  • Market Opportunities
    • Technological advancements and innovations in AI-based clinical trials
    • Major pharmaceutical companies are ensuring more joint ventures and partnerships with AI vendors
  • Market Challenges
    • Concerns associated with the adoption of EHR interoperability

Porter's Five Forces: A Strategic Tool for Navigating the AI-based Clinical Trials Market

Porter's five forces framework is a critical tool for understanding the competitive landscape of the AI-based Clinical Trials Market. It offers business organizations with a clear methodology for evaluating their competitive positioning and exploring strategic opportunities. This framework helps businesses assess the power dynamics within the market and determine the profitability of new ventures. With these insights, business organizations can leverage their strengths, address weaknesses, and avoid potential challenges, ensuring a more resilient market positioning.

PESTLE Analysis: Navigating External Influences in the AI-based Clinical Trials Market

External macro-environmental factors play a pivotal role in shaping the performance dynamics of the AI-based Clinical Trials Market. Political, Economic, Social, Technological, Legal, and Environmental factors analysis provides the necessary information to navigate these influences. By examining PESTLE factors, businesses can better understand potential risks and opportunities. This analysis enables business organizations to anticipate changes in regulations, consumer preferences, and economic trends, ensuring they are prepared to make proactive, forward-thinking decisions.

Market Share Analysis: Understanding the Competitive Landscape in the AI-based Clinical Trials Market

A detailed market share analysis in the AI-based Clinical Trials Market provides a comprehensive assessment of vendors' performance. Companies can identify their competitive positioning by comparing key metrics, including revenue, customer base, and growth rates. This analysis highlights market concentration, fragmentation, and trends in consolidation, offering vendors the insights required to make strategic decisions that enhance their position in an increasingly competitive landscape.

FPNV Positioning Matrix: Evaluating Vendors' Performance in the AI-based Clinical Trials Market

The Forefront, Pathfinder, Niche, Vital (FPNV) Positioning Matrix is a critical tool for evaluating vendors within the AI-based Clinical Trials Market. This matrix enables business organizations to make well-informed decisions that align with their goals by assessing vendors based on their business strategy and product satisfaction. The four quadrants provide a clear and precise segmentation of vendors, helping users identify the right partners and solutions that best fit their strategic objectives.

Strategy Analysis & Recommendation: Charting a Path to Success in the AI-based Clinical Trials Market

A strategic analysis of the AI-based Clinical Trials Market is essential for businesses looking to strengthen their global market presence. By reviewing key resources, capabilities, and performance indicators, business organizations can identify growth opportunities and work toward improvement. This approach helps businesses navigate challenges in the competitive landscape and ensures they are well-positioned to capitalize on newer opportunities and drive long-term success.

Key Company Profiles

The report delves into recent significant developments in the AI-based Clinical Trials Market, highlighting leading vendors and their innovative profiles. These include AiCure, LLC, Aiforia Technologies Oyj, Antidote Technologies, Inc., Ardigen S.A., Avantor, Inc., BioAge Labs, BioSymetrics Inc., Deep 6 AI Inc., Envisagenics, Euretos Services BV, Exscientia PLC, GNS Healthcare, Google LLC by Alphabet Inc., Innoplexus AG, InSilico Medicine, Intel Corporation, International Business Machines Corporation, Koninklijke Philips N.V., Median Technologies, Nuritas Limited, Pharmaceutical Pipeline Enhancement Strategies, LLC, Saama Technologies, Inc., Symplr Software LLC, Trials.ai, Inc. by ZS Associates, Inc., and Unlearn.AI, Inc..

Market Segmentation & Coverage

This research report categorizes the AI-based Clinical Trials Market to forecast the revenues and analyze trends in each of the following sub-markets:

  • Based on Component, market is studied across Services and Software.
  • Based on Function, market is studied across Adverse Event Detection, Data Collection & Analysis, Patient Recruitment & Screening, Predictive Modeling, and Trial Design & Optimization.
  • Based on Phase, market is studied across Phase-I, Phase-II, and Phase-III.
  • Based on Technology, market is studied across Machine Learning and Natural Language Processing.
  • Based on Application, market is studied across Cardiovascular Diseases, Infectious Diseases, Metabolic Diseases, Neurological Diseases, and Oncology.
  • Based on End-user, market is studied across Academic & Research Institutes, Contract Research Organization, Hospitals, and Pharmaceutical & Biopharmaceutical Companies.
  • Based on Region, market is studied across Americas, Asia-Pacific, and Europe, Middle East & Africa. The Americas is further studied across Argentina, Brazil, Canada, Mexico, and United States. The United States is further studied across California, Florida, Illinois, New York, Ohio, Pennsylvania, and Texas. The Asia-Pacific is further studied across Australia, China, India, Indonesia, Japan, Malaysia, Philippines, Singapore, South Korea, Taiwan, Thailand, and Vietnam. The Europe, Middle East & Africa is further studied across Denmark, Egypt, Finland, France, Germany, Israel, Italy, Netherlands, Nigeria, Norway, Poland, Qatar, Russia, Saudi Arabia, South Africa, Spain, Sweden, Switzerland, Turkey, United Arab Emirates, and United Kingdom.

The report offers a comprehensive analysis of the market, covering key focus areas:

1. Market Penetration: A detailed review of the current market environment, including extensive data from top industry players, evaluating their market reach and overall influence.

2. Market Development: Identifies growth opportunities in emerging markets and assesses expansion potential in established sectors, providing a strategic roadmap for future growth.

3. Market Diversification: Analyzes recent product launches, untapped geographic regions, major industry advancements, and strategic investments reshaping the market.

4. Competitive Assessment & Intelligence: Provides a thorough analysis of the competitive landscape, examining market share, business strategies, product portfolios, certifications, regulatory approvals, patent trends, and technological advancements of key players.

5. Product Development & Innovation: Highlights cutting-edge technologies, R&D activities, and product innovations expected to drive future market growth.

The report also answers critical questions to aid stakeholders in making informed decisions:

1. What is the current market size, and what is the forecasted growth?

2. Which products, segments, and regions offer the best investment opportunities?

3. What are the key technology trends and regulatory influences shaping the market?

4. How do leading vendors rank in terms of market share and competitive positioning?

5. What revenue sources and strategic opportunities drive vendors' market entry or exit strategies?

Table of Contents

1. Preface

  • 1.1. Objectives of the Study
  • 1.2. Market Segmentation & Coverage
  • 1.3. Years Considered for the Study
  • 1.4. Currency & Pricing
  • 1.5. Language
  • 1.6. Stakeholders

2. Research Methodology

  • 2.1. Define: Research Objective
  • 2.2. Determine: Research Design
  • 2.3. Prepare: Research Instrument
  • 2.4. Collect: Data Source
  • 2.5. Analyze: Data Interpretation
  • 2.6. Formulate: Data Verification
  • 2.7. Publish: Research Report
  • 2.8. Repeat: Report Update

3. Executive Summary

4. Market Overview

5. Market Insights

  • 5.1. Market Dynamics
    • 5.1.1. Drivers
      • 5.1.1.1. Need for artificial Intelligence which helps in boosting and improving clinical trials
      • 5.1.1.2. Rising needs to reduce healthcare costs and declining hardware costs
      • 5.1.1.3. Increased adoption of AI-based drug development technology by most of the pharmaceutical companies
    • 5.1.2. Restraints
      • 5.1.2.1. Lack of personal involvement leading to a rise in unemployment rates
      • 5.1.2.2. Possibility of a defective diagnosis
    • 5.1.3. Opportunities
      • 5.1.3.1. Technological advancements and innovations in AI-based clinical trials
      • 5.1.3.2. Major pharmaceutical companies are ensuring more joint ventures and partnerships with AI vendors
    • 5.1.4. Challenges
      • 5.1.4.1. Concerns associated with the adoption of EHR interoperability
  • 5.2. Market Segmentation Analysis
  • 5.3. Porter's Five Forces Analysis
    • 5.3.1. Threat of New Entrants
    • 5.3.2. Threat of Substitutes
    • 5.3.3. Bargaining Power of Customers
    • 5.3.4. Bargaining Power of Suppliers
    • 5.3.5. Industry Rivalry
  • 5.4. PESTLE Analysis
    • 5.4.1. Political
    • 5.4.2. Economic
    • 5.4.3. Social
    • 5.4.4. Technological
    • 5.4.5. Legal
    • 5.4.6. Environmental

6. AI-based Clinical Trials Market, by Component

  • 6.1. Introduction
  • 6.2. Services
  • 6.3. Software

7. AI-based Clinical Trials Market, by Function

  • 7.1. Introduction
  • 7.2. Adverse Event Detection
  • 7.3. Data Collection & Analysis
  • 7.4. Patient Recruitment & Screening
  • 7.5. Predictive Modeling
  • 7.6. Trial Design & Optimization

8. AI-based Clinical Trials Market, by Phase

  • 8.1. Introduction
  • 8.2. Phase-I
  • 8.3. Phase-II
  • 8.4. Phase-III

9. AI-based Clinical Trials Market, by Technology

  • 9.1. Introduction
  • 9.2. Machine Learning
  • 9.3. Natural Language Processing

10. AI-based Clinical Trials Market, by Application

  • 10.1. Introduction
  • 10.2. Cardiovascular Diseases
  • 10.3. Infectious Diseases
  • 10.4. Metabolic Diseases
  • 10.5. Neurological Diseases
  • 10.6. Oncology

11. AI-based Clinical Trials Market, by End-user

  • 11.1. Introduction
  • 11.2. Academic & Research Institutes
  • 11.3. Contract Research Organization
  • 11.4. Hospitals
  • 11.5. Pharmaceutical & Biopharmaceutical Companies

12. Americas AI-based Clinical Trials Market

  • 12.1. Introduction
  • 12.2. Argentina
  • 12.3. Brazil
  • 12.4. Canada
  • 12.5. Mexico
  • 12.6. United States

13. Asia-Pacific AI-based Clinical Trials Market

  • 13.1. Introduction
  • 13.2. Australia
  • 13.3. China
  • 13.4. India
  • 13.5. Indonesia
  • 13.6. Japan
  • 13.7. Malaysia
  • 13.8. Philippines
  • 13.9. Singapore
  • 13.10. South Korea
  • 13.11. Taiwan
  • 13.12. Thailand
  • 13.13. Vietnam

14. Europe, Middle East & Africa AI-based Clinical Trials Market

  • 14.1. Introduction
  • 14.2. Denmark
  • 14.3. Egypt
  • 14.4. Finland
  • 14.5. France
  • 14.6. Germany
  • 14.7. Israel
  • 14.8. Italy
  • 14.9. Netherlands
  • 14.10. Nigeria
  • 14.11. Norway
  • 14.12. Poland
  • 14.13. Qatar
  • 14.14. Russia
  • 14.15. Saudi Arabia
  • 14.16. South Africa
  • 14.17. Spain
  • 14.18. Sweden
  • 14.19. Switzerland
  • 14.20. Turkey
  • 14.21. United Arab Emirates
  • 14.22. United Kingdom

15. Competitive Landscape

  • 15.1. Market Share Analysis, 2023
  • 15.2. FPNV Positioning Matrix, 2023
  • 15.3. Competitive Scenario Analysis
  • 15.4. Strategy Analysis & Recommendation

Companies Mentioned

  • 1. AiCure, LLC
  • 2. Aiforia Technologies Oyj
  • 3. Antidote Technologies, Inc.
  • 4. Ardigen S.A.
  • 5. Avantor, Inc.
  • 6. BioAge Labs
  • 7. BioSymetrics Inc.
  • 8. Deep 6 AI Inc.
  • 9. Envisagenics
  • 10. Euretos Services BV
  • 11. Exscientia PLC
  • 12. GNS Healthcare
  • 13. Google LLC by Alphabet Inc.
  • 14. Innoplexus AG
  • 15. InSilico Medicine
  • 16. Intel Corporation
  • 17. International Business Machines Corporation
  • 18. Koninklijke Philips N.V.
  • 19. Median Technologies
  • 20. Nuritas Limited
  • 21. Pharmaceutical Pipeline Enhancement Strategies, LLC
  • 22. Saama Technologies, Inc.
  • 23. Symplr Software LLC
  • 24. Trials.ai, Inc. by ZS Associates, Inc.
  • 25. Unlearn.AI, Inc.

LIST OF FIGURES

  • FIGURE 1. AI-BASED CLINICAL TRIALS MARKET RESEARCH PROCESS
  • FIGURE 2. AI-BASED CLINICAL TRIALS MARKET SIZE, 2023 VS 2030
  • FIGURE 3. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • FIGURE 4. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY REGION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 5. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 6. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2023 VS 2030 (%)
  • FIGURE 7. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 8. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2023 VS 2030 (%)
  • FIGURE 9. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 10. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2030 (%)
  • FIGURE 11. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 12. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2030 (%)
  • FIGURE 13. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 14. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2023 VS 2030 (%)
  • FIGURE 15. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 16. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2023 VS 2030 (%)
  • FIGURE 17. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 18. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 19. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 20. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2030 (%)
  • FIGURE 21. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY STATE, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 22. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 23. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 24. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2030 (%)
  • FIGURE 25. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2023 VS 2024 VS 2030 (USD MILLION)
  • FIGURE 26. AI-BASED CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
  • FIGURE 27. AI-BASED CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023

LIST OF TABLES

  • TABLE 1. AI-BASED CLINICAL TRIALS MARKET SEGMENTATION & COVERAGE
  • TABLE 2. UNITED STATES DOLLAR EXCHANGE RATE, 2018-2023
  • TABLE 3. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, 2018-2030 (USD MILLION)
  • TABLE 4. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 5. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 6. AI-BASED CLINICAL TRIALS MARKET DYNAMICS
  • TABLE 7. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 8. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY SERVICES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 9. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY SOFTWARE, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 10. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 11. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY ADVERSE EVENT DETECTION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 12. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY DATA COLLECTION & ANALYSIS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 13. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PATIENT RECRUITMENT & SCREENING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 14. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PREDICTIVE MODELING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 15. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY TRIAL DESIGN & OPTIMIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 16. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 17. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE-I, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 18. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE-II, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 19. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE-III, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 20. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 21. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY MACHINE LEARNING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 22. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY NATURAL LANGUAGE PROCESSING, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 23. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 24. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY CARDIOVASCULAR DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 25. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY INFECTIOUS DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 26. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY METABOLIC DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 27. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY NEUROLOGICAL DISEASES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 28. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY ONCOLOGY, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 29. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 30. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY ACADEMIC & RESEARCH INSTITUTES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 31. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY CONTRACT RESEARCH ORGANIZATION, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 32. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY HOSPITALS, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 33. GLOBAL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHARMACEUTICAL & BIOPHARMACEUTICAL COMPANIES, BY REGION, 2018-2030 (USD MILLION)
  • TABLE 34. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 35. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 36. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 37. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 38. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 39. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 40. AMERICAS AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 41. ARGENTINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 42. ARGENTINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 43. ARGENTINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 44. ARGENTINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 45. ARGENTINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 46. ARGENTINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 47. BRAZIL AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 48. BRAZIL AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 49. BRAZIL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 50. BRAZIL AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 51. BRAZIL AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 52. BRAZIL AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 53. CANADA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 54. CANADA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 55. CANADA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 56. CANADA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 57. CANADA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 58. CANADA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 59. MEXICO AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 60. MEXICO AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 61. MEXICO AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 62. MEXICO AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 63. MEXICO AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 64. MEXICO AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 65. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 66. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 67. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 68. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 69. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 70. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 71. UNITED STATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY STATE, 2018-2030 (USD MILLION)
  • TABLE 72. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 73. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 74. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 75. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 76. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 77. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 78. ASIA-PACIFIC AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 79. AUSTRALIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 80. AUSTRALIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 81. AUSTRALIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 82. AUSTRALIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 83. AUSTRALIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 84. AUSTRALIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 85. CHINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 86. CHINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 87. CHINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 88. CHINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 89. CHINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 90. CHINA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 91. INDIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 92. INDIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 93. INDIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 94. INDIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 95. INDIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 96. INDIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 97. INDONESIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 98. INDONESIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 99. INDONESIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 100. INDONESIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 101. INDONESIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 102. INDONESIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 103. JAPAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 104. JAPAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 105. JAPAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 106. JAPAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 107. JAPAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 108. JAPAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 109. MALAYSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 110. MALAYSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 111. MALAYSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 112. MALAYSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 113. MALAYSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 114. MALAYSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 115. PHILIPPINES AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 116. PHILIPPINES AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 117. PHILIPPINES AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 118. PHILIPPINES AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 119. PHILIPPINES AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 120. PHILIPPINES AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 121. SINGAPORE AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 122. SINGAPORE AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 123. SINGAPORE AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 124. SINGAPORE AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 125. SINGAPORE AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 126. SINGAPORE AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 127. SOUTH KOREA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 128. SOUTH KOREA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 129. SOUTH KOREA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 130. SOUTH KOREA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 131. SOUTH KOREA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 132. SOUTH KOREA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 133. TAIWAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 134. TAIWAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 135. TAIWAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 136. TAIWAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 137. TAIWAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 138. TAIWAN AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 139. THAILAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 140. THAILAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 141. THAILAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 142. THAILAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 143. THAILAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 144. THAILAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 145. VIETNAM AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 146. VIETNAM AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 147. VIETNAM AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 148. VIETNAM AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 149. VIETNAM AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 150. VIETNAM AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 151. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 152. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 153. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 154. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 155. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 156. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 157. EUROPE, MIDDLE EAST & AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COUNTRY, 2018-2030 (USD MILLION)
  • TABLE 158. DENMARK AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 159. DENMARK AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 160. DENMARK AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 161. DENMARK AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 162. DENMARK AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 163. DENMARK AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 164. EGYPT AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 165. EGYPT AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 166. EGYPT AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 167. EGYPT AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 168. EGYPT AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 169. EGYPT AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 170. FINLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 171. FINLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 172. FINLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 173. FINLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 174. FINLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 175. FINLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 176. FRANCE AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 177. FRANCE AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 178. FRANCE AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 179. FRANCE AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 180. FRANCE AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 181. FRANCE AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 182. GERMANY AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 183. GERMANY AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 184. GERMANY AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 185. GERMANY AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 186. GERMANY AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 187. GERMANY AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 188. ISRAEL AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 189. ISRAEL AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 190. ISRAEL AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 191. ISRAEL AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 192. ISRAEL AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 193. ISRAEL AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 194. ITALY AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 195. ITALY AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 196. ITALY AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 197. ITALY AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 198. ITALY AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 199. ITALY AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 200. NETHERLANDS AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 201. NETHERLANDS AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 202. NETHERLANDS AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 203. NETHERLANDS AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 204. NETHERLANDS AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 205. NETHERLANDS AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 206. NIGERIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 207. NIGERIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 208. NIGERIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 209. NIGERIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 210. NIGERIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 211. NIGERIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 212. NORWAY AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 213. NORWAY AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 214. NORWAY AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 215. NORWAY AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 216. NORWAY AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 217. NORWAY AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 218. POLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 219. POLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 220. POLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 221. POLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 222. POLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 223. POLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 224. QATAR AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 225. QATAR AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 226. QATAR AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 227. QATAR AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 228. QATAR AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 229. QATAR AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 230. RUSSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 231. RUSSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 232. RUSSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 233. RUSSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 234. RUSSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 235. RUSSIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 236. SAUDI ARABIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 237. SAUDI ARABIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 238. SAUDI ARABIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 239. SAUDI ARABIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 240. SAUDI ARABIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 241. SAUDI ARABIA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 242. SOUTH AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 243. SOUTH AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 244. SOUTH AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 245. SOUTH AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 246. SOUTH AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 247. SOUTH AFRICA AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 248. SPAIN AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 249. SPAIN AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 250. SPAIN AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 251. SPAIN AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 252. SPAIN AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 253. SPAIN AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 254. SWEDEN AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 255. SWEDEN AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 256. SWEDEN AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 257. SWEDEN AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 258. SWEDEN AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 259. SWEDEN AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 260. SWITZERLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 261. SWITZERLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 262. SWITZERLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 263. SWITZERLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 264. SWITZERLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 265. SWITZERLAND AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 266. TURKEY AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 267. TURKEY AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 268. TURKEY AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 269. TURKEY AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 270. TURKEY AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 271. TURKEY AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 272. UNITED ARAB EMIRATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 273. UNITED ARAB EMIRATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 274. UNITED ARAB EMIRATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 275. UNITED ARAB EMIRATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 276. UNITED ARAB EMIRATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 277. UNITED ARAB EMIRATES AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 278. UNITED KINGDOM AI-BASED CLINICAL TRIALS MARKET SIZE, BY COMPONENT, 2018-2030 (USD MILLION)
  • TABLE 279. UNITED KINGDOM AI-BASED CLINICAL TRIALS MARKET SIZE, BY FUNCTION, 2018-2030 (USD MILLION)
  • TABLE 280. UNITED KINGDOM AI-BASED CLINICAL TRIALS MARKET SIZE, BY PHASE, 2018-2030 (USD MILLION)
  • TABLE 281. UNITED KINGDOM AI-BASED CLINICAL TRIALS MARKET SIZE, BY TECHNOLOGY, 2018-2030 (USD MILLION)
  • TABLE 282. UNITED KINGDOM AI-BASED CLINICAL TRIALS MARKET SIZE, BY APPLICATION, 2018-2030 (USD MILLION)
  • TABLE 283. UNITED KINGDOM AI-BASED CLINICAL TRIALS MARKET SIZE, BY END-USER, 2018-2030 (USD MILLION)
  • TABLE 284. AI-BASED CLINICAL TRIALS MARKET SHARE, BY KEY PLAYER, 2023
  • TABLE 285. AI-BASED CLINICAL TRIALS MARKET, FPNV POSITIONING MATRIX, 2023